Publication|Articles|October 15, 2024

Peers & Perspectives in Oncology

  • October I 2024
  • Pages: 40

Roundtable Roundup: First and Second Choices for Frontline RCC Therapy

During separate virtual live events, David A. Braun, MD, PhD, and Rana R. McKay, MD, surveyed oncologists on options for a patient with clear cell renal cell carcinoma (RCC) in the front line.

CASE SUMMARY

  • A 59-year-old African American woman was diagnosed with a left renal mass.
  • She underwent left radical nephrectomy in December 2019.
    • Clear cell RCC
    • T3aN0Mx, International Society of Urological Pathology grade 3
  • Nine months later, she reported pain in hips and left chest.
  • Radiographic diagnosis: stage IV RCC with osteolytic lesions in iliac crest and left fifth rib
  • ECOG performance status: 1
  • Laboratory results:
    • Hemoglobin level: 11.1 g/dL
    • Elevated liver function test results
    • Mild hypercalcemia (10.8 mg/dL)
    • Neutrophil and platelet counts: within normal limits

CASE UPDATE

The patient received nivolumab (Opdivo) plus ipilimumab (Yervoy).



Latest CME